供者克隆性造血增加同胞全合移植后急性移植物抗宿主病风险
该研究对363例接受首次异基因造血干细胞移植的AML/MDS患者的供者血样进行300基因靶向深度测序,以2%为最低变异等位基因频率界定克隆性造血(CH)。65例(18%)供者存在CH,最常见突变为DNMT3A、TET2、PPM1D和ASXL1。供者CH与6个月时II-IV级和III-IV级急性GVHD风险升高相关,而中性粒细胞和血小板恢复时间、复发率、移植相关死亡及无进展生存期无差异。
要点
- 供者CH在AML/MDS同胞全合移植中占18%,以DNMT3A和TET2突变为主。
- 供者CH使6个月II-IV级aGvHD风险升高(HR=2.4),III-IV级风险升高更显著(HR=3.8)。
- 供者CH未影响植入、复发、移植相关死亡或无进展生存。
核心结论
- 在AML/MDS同胞全合移植人群中,供者CH与6个月II-IV级和III-IV级急性GVHD风险增加相关。
研究设计与样本
- 对363例接受首次异基因造血干细胞移植的AML/MDS患者的供者血样进行300基因靶向深度测序,以最低变异等位基因频率2%界定CH。
主要发现
- 363例供者中65例(18%)存在CH,最常见突变为DNMT3A(31/65,48%)、TET2(16/65,25%)、PPM1D(5/65,8%)和ASXL1(7/65,11%)。
- 供者CH组与非CH组的中性粒细胞和血小板恢复时间、复发率、移植相关死亡及无进展生存期相当。
- 供者CH组6个月II-IV级aGvHD风险升高(HR=2.4,95%CI=1.6-3.6,p<0.001),III-IV级aGvHD风险亦升高(HR=3.8,95%CI=1.6-8.9,p=0.003)。
临床怎么用
- 在同胞全合移植供者评估中,可考虑对供者血样进行CH靶向测序以识别aGvHD高风险配对。
- 对供者存在CH的受者,需加强aGvHD监测与预防策略。
局限性
- 原文指出需进一步研究供者CH增加aGvHD的机制及治疗干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal hematopoiesis (CH) is associated with older age and an increased risk of myeloid malignancies and cardiovascular complications. We analyzed donor DNA samples in patients with AML/MDS who underwent first allogeneic stem cell transplant (SCT) to investigate the association between donor CH and transplant outcomes. We performed targeted deep sequencing of 300 genes on donor blood samples and identified CH with the minimum variant allele frequency of 2%. Among 363 donors, 65 (18%) had CH. The most frequently mutated genes were DNMT3A (31 of 65; 48%), TET2 (16 of 65; 25%), PPM1D (5 of 65, 8%), and ASXL1 (7 of 65; 11%). Transplant outcomes: time to neutrophil and platelet recovery, relapse incidence, transplant-related mortality and progression-free survival, were comparable by donor CH. However, risk of grade II-IV and III-IV acute graft versus host disease (aGvHD) at 6 months after transplant was higher with donor CH vs. without donor CH (hazard ratio (HR) = 2.4, 95% Confidence Interval (CI) = 1.6-3.6, p < 0.001 and HR = 3.8, 95% CI = 1.6-8.9, p = 0.003). In this homogenous population of AML/MDS patients, donor CH was associated with increased risk of grade II-IV and III-IV aGvHD. Further studies to investigate the mechanisms of increased aGvHD and therapeutic interventions to improve aGvHD in the context of donor CH are warranted.
引用
- Oran B, Champlin RE, Wang F, et al. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2021. PMID: 34135465. doi:10.1038/s41375-021-01312-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。